Laughlin Family Foundation Research Grant for High-Grade Uterine Cancer supports researchers studying treatment resistance in high-grade endometrial cancer to advance more durable, personalized care.
Funder: Foundation for Women's Cancer
Due Dates (Anticipated): December 2026 (Full proposals) | October 2027 (LOI)
Funding Amounts: $50,000 for one year
Summary: Supports innovative research addressing therapeutic resistance and advancing treatment of high-grade endometrial cancer.
Key Information: Research must take place at a U.S. institution; applicants need SGO membership, an SGO-member co-investigator, or SGO sponsorship.
Funded by the Laughlin Family Foundation and administered through the Foundation for Women’s Cancer (FWC), this opportunity supports innovative research advancing treatment of high-grade endometrial cancer, particularly the challenge of therapeutic resistance. It is the Laughlin Family Foundation’s fourth FWC research grant for high-grade uterine cancer.
Research may investigate hormonal or endocrine resistance, immune escape, lineage plasticity, tumor-microenvironment interactions, the microbiome’s role in inflammation and treatment response, or biomarkers predicting responsiveness to current or emerging therapies. Priority goes to projects using cutting-edge technologies and translational approaches to identify actionable targets and accelerate therapeutic development. The goal is more durable, personalized care for patients with aggressive endometrial cancers.